Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
Дата публикации: 24-06-2026 07:06:00

Evidence for efficacy is based on the results from the TROPION-Breast02 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer5508-07-2026
2EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan0526-06-2026
3FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC013.1329-07-2026
4EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
5FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)017.0225-06-2026
6EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
7FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies014.5912-08-2026
8Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
9STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class04.2314-08-2026
10FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer011.8510-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: www.esmo.org.